Funding Round
Sinaptica Therapeutics secures €18M Series A for personalized TMS Alzheimer's therapy
Fierce Biotech3/27/2026·03/27/26🌐 Europe
Summary
Genoa-based Sinaptica Therapeutics raised €18M Series A led by Sofinnova Partners, with Eureka Capital Partners and CDP Venture Capital. Sinaptica's personalized TMS protocol, guided by individual connectome mapping from fMRI, showed 35% reduction in cognitive decline versus standard TMS in a 65-patient Phase 2 trial recently published in Brain.
Why it matters
The connectome-guided personalization approach is backed by Stanford's pioneering SCC DBS work. Sinaptica translating this principle to non-invasive TMS for Alzheimer's represents a premium precision medicine opportunity in a market desperate for effective interventions.
#TMS#Alzheimers#Closed-Loop#Neuroimaging#Europe
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in